Edgewise Therapeutics, Inc. (EWTX) Stock Price & Analysis

Edgewise Therapeutics, Inc. (EWTX) rose 2.67% to USD 43.07 as of September 8, 2026 at 04:16 UTC, according to Nexqual real-time market data.

EWTX last closed at USD 43.07; the session ranged USD 41.6–43.33 on volume of 826,754 shares. Market capitalization is —, with a 52-week range of USD 13.69–48.4 (NMS). Source: Nexqual, September 8, 2026 at 04:16 UTC.

Key Statistics (as of September 8, 2026 at 04:16 UTC)

Technical Analysis (EWTX)

Nexqual's technical model rates EWTX "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 04:16 UTC.

From Edgewise Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Key components of our strategy to achieve this vision include: 7 Table of Contents Our Proprietary Drug Discovery Platform Our precision medicine muscle platform enables the discovery and development of therapies with disease modifying potential Muscle is the most abundant tissue in the body.
• Furthermore, this limited durability is problematic because re-administration after the first dose is currently not possible. 11 Table of Contents In June 2023, the FDA approved Sarepta's Biologics License Application seeking accelerated approval of their microdystrophin gene therapy, Elevidys (delandistrogene moxeparvovec), for the treatment of ambulant individuals with Duchenne between the ages of four to five years.
• Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule engineering to build our proprietary, muscle focused drug discovery platform.
• We believe our muscle-focused discovery program offer substantial opportunities for us to expand into other severe muscle diseases for which there are limited or no approved treatments. ​ Our Pipeline ​ Using our proprietary drug discovery platform, we are developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of muscle diseases.

Partnerships

• In October 2023, the FDA granted AGAMREE (vamorolone), a novel steroid therapy, approval in Duchenne patients aged 2 years and older, and Catalyst Pharmaceuticals, Inc. has commercialized this product in the United States following its North America exclusive 10 Table of Contents license deal with Santhera.
• In June 2025, we reported initial results from the FOX Phase 2 placebo-controlled trial in participants with Duchenne previously treated with gene therapy that also supported that sevasemten 10 mg has the potential to reduce the rate of functional decline. ​ Natural History Study In 2022, we commenced an observational natural history study being conducted in collaboration with the GRASP-LGMD Consortium.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:16 UTC. This page is informational and not investment advice.